State of New Jersey Common Pension Fund D Has $1.89 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

State of New Jersey Common Pension Fund D lessened its stake in LivaNova PLC (NASDAQ:LIVN) by 3.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,872 shares of the company’s stock after selling 1,667 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.08% of LivaNova worth $1,893,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Point72 Asset Management L.P. raised its position in shares of LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after buying an additional 806,374 shares in the last quarter. Geode Capital Management LLC increased its stake in LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after acquiring an additional 8,331 shares during the last quarter. Victory Capital Management Inc. lifted its stake in LivaNova by 16.6% during the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock worth $49,130,000 after purchasing an additional 133,401 shares during the last quarter. Emerald Advisers LLC boosted its holdings in shares of LivaNova by 2.1% in the 3rd quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock valued at $36,542,000 after purchasing an additional 14,302 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock valued at $32,678,000 after purchasing an additional 93,311 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is owned by corporate insiders.

LivaNova Stock Performance

NASDAQ LIVN opened at $49.50 on Tuesday. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of 117.86 and a beta of 1.00. LivaNova PLC has a twelve month low of $43.15 and a twelve month high of $64.47. The stock has a fifty day simple moving average of $47.94 and a 200 day simple moving average of $49.64. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Analyst Ratings Changes

LIVN has been the subject of several recent analyst reports. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, January 28th. Robert W. Baird raised their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Mizuho dropped their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Finally, StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.